Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1
Observational studyHumansOther animals
- Design
- Observational study
- Subjects
- 135 diabetic nephropathy cases and 107 diabetic controls without nephropathy
- What was measured
- CNDP1 exon 2 trinucleotide repeat polymorphism, serum carnosinase activity, and fibronectin, collagen VI and TGF-beta production by cultured podocytes and mesangial cells under high glucose.
What the authors reported
A CNDP1 trinucleotide repeat variant (the Mannheim allele) was more common in diabetic patients without nephropathy than in those with it (P = 0.0028, odds ratio 2.56, 95% CI 1.36 to 4.84) and was associated with lower serum carnosinase activity. In cultured podocytes and mesangial cells, carnosine inhibited the increases in fibronectin, collagen VI and TGF-beta produced by 25 mmol/l glucose.
Limits of this study
Case-control genetic association; the cell experiments are in vitro and do not test carnosine supplementation in people. Full text not read.
Source
PubMed 16046297 · doi:10.2337/diabetes.54.8.2320
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.